These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29876266)

  • 1. Development and validation of a novel dementia of Alzheimer's type (DAT) score based on metabolism FDG-PET imaging.
    Popuri K; Balachandar R; Alpert K; Lu D; Bhalla M; Mackenzie IR; Hsiung RG; Wang L; Beg MF;
    Neuroimage Clin; 2018; 18():802-813. PubMed ID: 29876266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using machine learning to quantify structural MRI neurodegeneration patterns of Alzheimer's disease into dementia score: Independent validation on 8,834 images from ADNI, AIBL, OASIS, and MIRIAD databases.
    Popuri K; Ma D; Wang L; Beg MF
    Hum Brain Mapp; 2020 Oct; 41(14):4127-4147. PubMed ID: 32614505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying brain metabolism from FDG-PET images into a probability of Alzheimer's dementia score.
    Yee E; Popuri K; Beg MF;
    Hum Brain Mapp; 2020 Jan; 41(1):5-16. PubMed ID: 31507022
    [No Abstract]   [Full Text] [Related]  

  • 5. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.
    Arbizu J; Prieto E; Martínez-Lage P; Martí-Climent JM; García-Granero M; Lamet I; Pastor P; Riverol M; Gómez-Isla MT; Peñuelas I; Richter JA; Weiner MW;
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1394-405. PubMed ID: 23715905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinded Clinical Evaluation for Dementia of Alzheimer's Type Classification Using FDG-PET: A Comparison Between Feature-Engineered and Non-Feature-Engineered Machine Learning Methods.
    Ma D; Yee E; Stocks JK; Jenkins LM; Popuri K; Chausse G; Wang L; Probst S; Beg MF
    J Alzheimers Dis; 2021; 80(2):715-726. PubMed ID: 33579858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.
    Ou YN; Xu W; Li JQ; Guo Y; Cui M; Chen KL; Huang YY; Dong Q; Tan L; Yu JT;
    Alzheimers Res Ther; 2019 Jun; 11(1):57. PubMed ID: 31253185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases- A simulation study combining multi-center data and ADNI-data.
    Sekine T; Buck A; Delso G; Kemp B; Ter Voert EEGW; Huellner M; Veit-Haibach P; Kaushik S; Wiesinger F; Warnock G;
    PLoS One; 2020; 15(6):e0233886. PubMed ID: 32492074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.
    Mosconi L; Mistur R; Switalski R; Tsui WH; Glodzik L; Li Y; Pirraglia E; De Santi S; Reisberg B; Wisniewski T; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):811-22. PubMed ID: 19142633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine Learning Based Multimodal Neuroimaging Genomics Dementia Score for Predicting Future Conversion to Alzheimer's Disease.
    Mirabnahrazam G; Ma D; Lee S; Popuri K; Lee H; Cao J; Wang L; Galvin JE; Beg MF;
    J Alzheimers Dis; 2022; 87(3):1345-1365. PubMed ID: 35466939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep learning based diagnosis of Alzheimer's disease using FDG-PET images.
    Kishore N; Goel N
    Neurosci Lett; 2023 Nov; 817():137530. PubMed ID: 37858874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.